Introduction: This is a clinically heterogeneous entity with suboptimal results to known modalities of treatment globally. The clinical heterogeneity of this clinical syndrome is due to variable etiopathogenetic mechanisms involved in the final manifestation of symptoms. Hence it is but logical to categorize these patients into phenotypes based on suspected underlying etiology, in order to institute a treatment strategy specific to that group. Methodology: Diagnosed as BPS as per the ESSIC guidelines, 84 consecutive patients were categorized into four clinical phenotypes (CP), allergy, dysfunctional voiding, neuropathic pain and presence of Hunner's ulcer and labeled as CP 1 through 4 respectively. Patients could qualify to be categorized in more than one category. They were administered oral PPS and treatment specific to the CP. The patients from CP1 to 3 received hydroxyzine, clonazepam, and amitriptyline respectively. Patients with Hunners lesion underwent hydro distension and ablation of Hunners lesion followed by intravesical heparin and hydrocortisone solution. The patients were scored clinically and assessed as per prevailing scoring system and results were tabulated at 1,3 and 6 months. Results: Out of 86 patients, 78 were found evaluable. The CP groups from 1-4 were found to have 24,46,14,18 patients respectively. Many patients qualified for being categorized in more than one category. The response rate at 6 months was 71%, 76%, 57%, and 78% respectively for each CP while the response of overall cohort was 76%. Conclusion: Clinical phenoptyping based on features indicative of etiology helps to improve outcomes by guiding treatments focused towards addressing the specific pathological processes.